TruScreen Lifts FY26 Revenue 41% to NZ$2.4M Despite Order Timing Delays
TruScreen lifts FY2026 revenue 41% despite order timing delays
TruScreen Group (ASX: TRU) has issued updated revenue guidance, projecting NZ$2.4 million in product sales revenue for the financial year ending 31 March 2026, representing 41% year-on-year growth. Total revenue is expected to reach NZ$2.7 million, a 28% increase on FY2025. Whilst these figures sit below the company’s previous guidance of NZ$2.8 million, the variance stems from order timing rather than weakened demand, with a signed Uzbekistan contract awaiting payment and a Zimbabwe validation programme delay pushing 10,000 Single Use Sensor (SUS) units into FY2027.
The company attributes the shortfall to two specific timing factors. A signed sales contract with Uzbekistan remains pending payment before shipment can proceed, whilst delays in Zimbabwe’s validation programme have deferred a substantial consumables order into the next financial year. Management emphasises these represent deferred revenue rather than lost business opportunities.
When big ASX news breaks, our subscribers know first
What is cervical screening technology and why does it matter?
TruScreen has developed an AI-enabled cervical screening device that detects abnormalities in cervical tissue in real time through measurements of optical and electrical responses. Unlike traditional screening methods that require laboratory processing of biological samples, the TruScreen Ultra® device delivers immediate results at the point of care, eliminating the need for specialised laboratory infrastructure, trained cytologists, or follow-up appointments for results.
The technology addresses a critical gap in emerging markets where laboratory capacity constraints often limit access to cervical cancer screening. The device is registered for clinical use across multiple jurisdictions, providing broad market access for commercial deployment. Key regulatory approvals include:
- CE Mark/EC certification (European Union)
- TGA approval (Australia)
- NMPA registration (China)
- MHRA registration (United Kingdom)
- SFDA approval (Saudi Arabia)
- Ministry of Health approvals in Vietnam, Israel, Ukraine, and the Philippines
Order delays push revenue into FY2027
Two material orders have shifted from FY2026 into subsequent periods due to administrative and validation timing factors. The Uzbekistan situation involves a signed contract where the company is awaiting payment receipt before proceeding with shipment, representing deferred rather than cancelled business.
The Zimbabwe scenario reflects a delay in the validation programme, which has pushed an anticipated second order of 10,000 SUS units into FY2027. This represents significant consumables revenue that will now contribute to the following financial year’s results.
| Market | Status | Expected Timing |
|---|---|---|
| Uzbekistan | Contract signed, awaiting payment | Shipment pending payment receipt |
| Zimbabwe | Validation delay | 10,000 SUS units deferred to FY2027 |
Both orders remain in the pipeline and represent visible near-term revenue that has shifted between reporting periods rather than evaporated, potentially setting up a stronger start to FY2027.
Earnings outlook and investment in market expansion
TruScreen expects to report a loss of approximately NZ$2.2 million for FY2026, similar to FY2025 results. This reflects additional market access development costs. The Australian Research & Development tax refund is expected to be NZ$200,000 lower than FY2025 due to reduced R&D expenditure.
During FY2026, TruScreen invested in expanding its distributor network and market presence across Uzbekistan, India, Indonesia, and selected African markets. These investments are intended to build the critical mass of product adoption and market access required to support the company’s path to sustainable profitability over the medium term.
The loss profile reflects a market-building phase where distribution infrastructure investment precedes scaled revenue generation. Management positions current spending as necessary groundwork for future profitability rather than operational inefficiency.
Clinical validation strengthens commercial case
Recent publication of a large-scale clinical study by the Chinese Obstetricians and Gynaecologists Association (COGA) has generated positive interest in TruScreen’s AI-enabled technology. The study tracked 15,000 patients over 4 years, providing substantial real-world evidence of the device’s performance in clinical practice.
This clinical validation complements existing recognition of TruScreen technology in established medical guidelines. The device has been included in the Chinese Society for Colposcopy and Cervical Pathology’s China Cervical Cancer Screening Management Guideline. In December 2023, TruScreen technology was added to Vietnam’s Ministry of Health approved National Technical List for use across public and private healthcare sectors. The device was also added to Russian screening guidelines for cervical cancer in 2024.
These endorsements from medical authorities provide third-party credibility that supports commercial discussions with healthcare systems and distributors evaluating the technology.
The next major ASX story will hit our subscribers first
Path to sustainable profitability
TruScreen’s stated objective centres on building critical mass for sustainable profitability over the medium term through expanded device installations and recurring consumables revenue. The company has established a global footprint with commercial traction across multiple markets:
- 200+ devices installed globally
- 200,000+ examinations performed in FY2024
- Distributors established in 29 countries
The installed base spans China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. FY2024 examination volumes of over 200,000 procedures (based on SUS sales) demonstrate active utilisation of deployed devices, supporting the transition from one-off device sales to a more predictable consumables-driven revenue model.
Each installed device represents a platform for ongoing SUS consumables sales, with examination volumes providing visibility into usage patterns. The distributor network across 29 countries establishes market access infrastructure to support continued deployment, whilst recent clinical validation and guideline inclusions strengthen the commercial case for healthcare system adoption. The company positions itself as moving beyond proof-of-concept into a scaling phase where accumulated installations and distributor relationships support revenue growth towards profitability.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit the ASX.